Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

12112studies shown

Showing 5,257-5,268 of 12,112

Drug study icon

CompletedNCT04118127

A Clinical Pharmacology study of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

This study is completed. It focuses on schizophrenia and currently lists study information in Japan.

In Tokyo

SchizophreniaOtherFrom 18 Years to 64 Years

Countries: Japan
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Condition: Schizophrenia

Other study type icon

Active Not RecruitingNCT07295444

CreNeuriS CNS Herbal Nutrition Capsules for depression

This study is active but not recruiting in China. It is testing CreNeuriS CNS Herbal Nutrition Capsules for depression.

In Nanchang

Depression, AnxietyOtherFrom 18 Years to 65 Years

Countries: China
Sponsor: Second Affiliated Hospital of Nanchang University
Condition: Depression, Anxiety

Drug study icon

TerminatedNCT05169710

Investigational Drug for depression

This study was terminated in the United States, in Canada, in Bulgaria, .... It is testing investigational Drug for depression.

Multiple locations, including Huntsville

Depression, BipolarityOtherFrom 18 Years to 65 Years

Countries: United States, Canada, Bulgaria, ...
Sponsor: Sumitomo Pharma America, Inc.
Condition: Depression, Bipolarity

Behavioral study icon

CompletedNCT02009371

A Clinical Study of Light Therapy on Depressive Episodes of Bipolarity

This study is completed. It focuses on bipolarity and currently lists study information in China.

In Beijing

Bipolarity, DepressionOtherFrom 18 Years to 65 Years

Countries: China
Sponsor: Peking University
Condition: Bipolarity, Depression

Drug study icon

CompletedNCT05402111

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Little Rock

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05463770

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in people with Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Little Rock

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05542264

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Little Rock

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05628103

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Anaheim

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT06309277

Of Single and Multiple Oral Doses of GM-1020 for Depression

This study is completed in the United Kingdom. It is testing of Single and Multiple Oral Doses of GM-1020 for Depression.

In Manchester

DepressionOtherFrom 18 Years to 65 Years

Countries: United Kingdom
Sponsor: Gilgamesh Pharmaceuticals
Condition: Depression

Drug study icon

TerminatedNCT04109950

Safety study of investigational Drug in schizophrenia

This study was terminated in the United States, in Bulgaria, in Colombia, .... It is testing investigational Drug for schizophrenia.

Multiple locations, including Little Rock

SchizophreniaOtherFrom 13 Years to 65 Years

Countries: United States, Bulgaria, Colombia, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT04038957

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

This study is completed in the United Kingdom. It focuses on schizophrenia.

In London

SchizophreniaOtherFrom 18 Years to 45 Years

Countries: United Kingdom
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT04369391

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

This study is completed. It focuses on schizophrenia and currently lists study information in the United States.

Multiple locations, including Little Rock

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.